KBC Group NV Reduces Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

KBC Group NV reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 75.5% in the second quarter, Holdings Channel.com reports. The fund owned 36,572 shares of the biopharmaceutical company’s stock after selling 112,868 shares during the period. KBC Group NV’s holdings in Regeneron Pharmaceuticals were worth $19,201,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock valued at $5,966,767,000 after buying an additional 121,545 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Regeneron Pharmaceuticals by 4.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock valued at $1,379,467,000 after acquiring an additional 89,579 shares during the period. Amundi boosted its position in shares of Regeneron Pharmaceuticals by 3.4% in the first quarter. Amundi now owns 1,603,901 shares of the biopharmaceutical company’s stock valued at $979,794,000 after acquiring an additional 52,166 shares during the period. Goldman Sachs Group Inc. grew its stake in Regeneron Pharmaceuticals by 18.0% during the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock valued at $724,984,000 after acquiring an additional 174,056 shares in the last quarter. Finally, American Century Companies Inc. increased its holdings in Regeneron Pharmaceuticals by 2.1% during the 1st quarter. American Century Companies Inc. now owns 722,467 shares of the biopharmaceutical company’s stock worth $458,211,000 after acquiring an additional 14,921 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on REGN shares. Canaccord Genuity Group reissued a “buy” rating and issued a $850.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, October 23rd. Rothschild & Co Redburn started coverage on Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They set a “buy” rating and a $890.00 price objective for the company. Jefferies Financial Group boosted their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a research report on Wednesday, August 27th. Raymond James Financial raised Regeneron Pharmaceuticals to a “moderate buy” rating in a report on Tuesday, September 2nd. Finally, Bank of America boosted their price target on shares of Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the stock an “underperform” rating in a research note on Wednesday, October 29th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $789.91.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the sale, the director owned 2,352 shares of the company’s stock, valued at $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the sale, the vice president owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 1.9%

Shares of NASDAQ:REGN opened at $694.99 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.72. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $803.41. The company has a market cap of $73.04 billion, a P/E ratio of 16.64, a PEG ratio of 2.03 and a beta of 0.31. The stock’s fifty day moving average price is $596.36 and its 200-day moving average price is $570.46.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The business had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.Regeneron Pharmaceuticals’s revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $12.46 EPS. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be given a dividend of $0.88 per share. The ex-dividend date is Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is 8.43%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.